PRDM16-DT是一种新型的lncRNA,可调节阿尔茨海默氏病中天体细胞的功能
Sophie Schröder1, Ulrike Fuchs1, Verena Gisa1
1Department for Systems Medicine and Epigenetics, German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
Acta neuropathologica
|August 29, 2024
概括
长非编码RNAPRDM16-DT支持星细胞功能和神经元健康. 它在阿尔茨海默病中的降低调节突出了其作为神经退行性疾病治疗点的潜力.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 星球细胞对于神经元的支持至关重要,但它们的功能障碍有助于神经退行性疾病,如阿尔茨海默氏症 (AD).
- 长非编码RNAs (lncRNAs) 正在成为关键调节者,但它们在天体细胞功能和AD中的作用仍未得到充分研究.
- 研究主要集中在蛋白质编码基因上,忽视了神经系统疾病中非编码RNA的调节潜力.
研究的目的:
- 确定和描述涉及天体细胞生物学的新型lncRNAs的功能及其与阿尔茨海默病相关性.
- 研究lncRNAPRDM16-DT在维持星细胞平衡和支持神经元功能的作用.
- 探索PRDM16-DT作为神经退行性疾病的潜在治疗点.
主要方法:
- 识别大脑丰富的lncRNAs,特别是PRDM16-DT,在人类星球细胞中高度表达.
- 对阿尔茨海默病患者和模型中的PRDM16-DT及其小鼠同类 (Prdm16os) 表达水平的分析.
- 功能性研究涉及撞击和CRISPR介导的PRDM16-DT/Prdm16os在星球细胞中的过度表达.
- 研究与RE1-沉默转录因子 (Rest) 和多抑制复合体2 (PRC2) 的分子相互作用.
主要成果:
- 人类大脑中PRDM16-DT的含量很高,特别是在星球细胞中.
- 在阿尔茨海默病的大脑和模型中,PRDM16-DT/Prdm16os的表达是下调的.
- 敲除PRDM16-DT/Prdm16os会通过影响谷氨酸的摄取,乳酸释放和神经脊柱密度来损害天体细胞平衡和神经元支持.
- 使用CRISPR的Prdm16os过度表达部分挽救了AD相关刺激引起的天体细胞功能缺陷.
结论:
- PRDM16-DT在维持星细胞功能和支持神经元健康方面发挥着至关重要的作用.
- PRDM16-DT的失调与阿尔茨海默氏病的发病有关.
- PRDM16-DT是神经退行性疾病的有前途的新疗法标,涉及天体细胞功能障碍.
更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
787
05:40AAV Systems and Mouse Models for Investigating Ectopic Expression of Neurod1 in Transduced Cells at Subacute and Chronic Times Post-Ischemic Stroke
Published on: November 29, 2024
420
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
01:26Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454
01:37Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K